期刊
PHARMACOLOGY & THERAPEUTICS
卷 201, 期 -, 页码 202-213出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2019.05.012
关键词
Inflammation; Cancer; Pancreatic ductal adenocarcinoma; Immunotherapy; Immune evasion; Treatment paradigms; T cells; Macrophages; Neutrophils; Tumor microenvironment; Immunosurveillance; Vaccines; Therapeutic resistance; Metastasis; Clinical trials
资金
- National Institutes of Health [R01 CA197916, T32 CA009140, U01 CA224193]
- 2017 Stand Up to Cancer (SU2C) Innovative Research Grant [SU2C-AACR-IRG 13-17]
- Robert L. Fine Cancer Research Foundation
Inflammation is a hallmark of cancer. For pancreatic ductal adenocarcinoma (PDAC), malignant cells arise in the context of a brisk inflammatory cell infiltrate surrounded by dense fibrosis that is seen beginning at the earliest stages of cancer conception. This inflammatory and fibrotic milieu supports cancer cell escape from immune elimination and promotes malignant progression and metastatic spread to distant organs. Targeting this inflammatory reaction in PDAC by inhibiting or depleting pro-tumor elements and by engaging the potential of inflammatory cells to acquire anti-tumor activity has garnered strong research and clinical interest. Herein, we describe the current understanding of key determinants of inflammation in PDAC; mechanisms by which inflammation drives immune suppression; the impact of inflammation on metastasis, therapeutic resistance, and clinical outcomes; and strategies to intervene on inflammation for providing therapeutic benefit. (C) 2019 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据